The business combination provides a Nasdaq listing with access to the $50M Lincoln Park equity line, but the core biotech remains pre-revenue with mounting losses and a large accumulated deficit. The $27.5M senior secured note ranks senior to all obligations, adding leverage risk. Monitor for clinical pipeline catalysts (VX-A901 AML program), potential additional equity dilution under the ELOC, and remediation of the material weakness in internal controls. The substantial SPAC redemption ($273M) left minimal cash from the trust, making the HTC and LPC financings critical for survival.
Price Chart
Executive Summary
Veraxa Biotech AG completed a de-SPAC business combination on June 10, 2026, merging with Voyager Acquisition Corp. Concurrently, the company closed a $27.5M senior secured note with High Trail Capital and entered into a $50M equity line with Lincoln Park Capital. The filing reveals an accumulated deficit of CHF 98.5M, material weakness in internal controls, and a net working capital deficit of CHF 3.7M as of December 31, 2025, with operating losses widening to CHF 66.6M in 2025 from CHF 28.1M in 2024.
Key Facts
- Business combination consummated June 10, 2026, with 141,407,813 ordinary shares outstanding.
- Net loss for 2025 was CHF 66,613,990, compared to CHF 28,132,971 in 2024, a 137% increase.
- Revenue was minimal at CHF 23,426 in 2025, from CHF 0 in 2024.
- Accumulated deficit reached CHF 98,478,340 as of December 31, 2025.
- General and administrative expenses surged 174% to CHF 46.9M, driven by CHF 40.2M in stock-based compensation.
- Research and development expenses increased 63% to CHF 10.3M.
- Cash and cash equivalents fell to CHF 1.6M from CHF 5.4M year-over-year.
- Cash used in operations was CHF 9.9M in 2025 vs CHF 7.7M in 2024.
- Negative shareholders' equity of CHF 15.8M at operating subsidiary level; PubCo had negative equity of CHF 26.6M pro forma.
- High Trail Capital received a $27.5M senior secured note with warrants, secured by all PubCo assets.
- 25,217,315 SPAC shares were redeemed for approximately $273M, severely depleting trust proceeds.
- Material weakness in internal control over financial reporting identified as of Dec 31, 2025.
Financial Impact
Net loss of CHF 66.6M in 2025 vs CHF 28.1M in 2024; cash burn of CHF 9.9M; $27.5M secured debt added to capital structure with accumulated deficit of CHF 98.5M and negative equity.
Risk Factors
- Deeply negative shareholders' equity of CHF 15.8M (operating subsidiary) and CHF 26.6M (PubCo pro forma).
- Pre-revenue stage with only CHF 23,426 in 2025 revenue and no product sales.
- Material weakness in internal controls over financial reporting.
- $27.5M senior secured note with 15-month maturity ranks senior to all assets, creating debt service pressure.
- High cash burn rate with only CHF 1.6M cash at Dec 31, 2025, prior to post-closing financing.
- Dilution risk from warrants (22.7M outstanding at $11.50), ELOC ($50M), and CF&CO fee shares ($7M).
- Dependence on future financing through the Lincoln Park ELOC and potential additional equity/debt offerings.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001829126-26-006546 |
| Document: veraxabiotech_ex1-1.htm | 0001829126-26-006546 |
| Document: veraxabiotech_ex4-11.htm | 0001829126-26-006546 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $1.11 | awaiting T+20 | — | $1.00 (−9.91%) |
Sep 4, 2026 7w ago | 6-K | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $1.00 (−43.18%) |
Sep 4, 2026 7w ago | Press Release | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $1.00 (−43.18%) |
Aug 24, 2026 9w ago | 6-K | $1.78 $1.46 | ▼ −17.98% | ▼ −17.99% | $1.00 (−43.82%) |
Aug 10, 2026 11w ago | EFFECT | $1.85 $1.60 | ▲ +13.51% | ▲ +12.60% | $1.00 (+45.95%) |
Aug 7, 2026 11w ago | EFFECT | $1.99 $1.76 | ▲ +11.56% | ▲ +11.16% | $1.00 (+49.75%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $1.00 (+45.36%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $1.00 (+45.36%) |
Jul 27, 2026 13w ago | 6-K | $1.98 $1.73 | ▼ −12.63% | ▼ −16.01% | $1.00 (−49.49%) |
Jul 27, 2026 13w ago | 6-K | $2.01 $1.78 | ▼ −11.44% | ▼ −14.74% | $1.00 (−50.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers